Our esteemed panelists will discuss recent antitrust actions targeting pharmaceutical prices, including the FTC's report on PBMs and its complaint against PBMs regarding insulin, state AG actions against PBMs and other pharmaceutical industry participants, and a comparison to excessive pharmaceutical pricing actions in the UK, among other topics.
